Ascletis Advances Obesity Pipeline with Phase I Trial for Oral…

Event summary

Ascletis initiated a U.S. Phase I trial for ASC36, an oral amylin receptor peptide agonist, after FDA IND clearance.
ASC36 demonstrated 6-8% oral bioavailability and up to 13.2% weight reduction in non-human primates.
The subcutaneous version showed 32% and 91% greater weight loss than competitors in rat models.
This is Ascletis' fourth Phase I peptide study in 2026, validating its POTENT oral delivery technology.

The big picture

Ascletis is expanding its obesity treatment pipeline with ASC36, an oral amylin peptide that could offer a differentiated option in a competitive market dominated by injectable GLP-1 agonists. The company's proprietary POTENT technology positions it as a leader in oral peptide delivery, potentially disrupting the obesity treatment landscape. This Phase I trial follows three others in 2026, demonstrating Ascletis' aggressive push into metabolic disease therapeutics.

What we're watching

Clinical Validation: Whether ASC36's preclinical efficacy translates to human trials, particularly its superior weight loss per milligram.
Technology Scalability: The pace at which Ascletis can scale manufacturing given ASC36's lower expected dosing requirements.
Pipeline Diversification: How ASC36 integrates with Ascletis' broader portfolio of obesity treatments, including its oral and injectable programs.